Within Fig 3, Fig 3A and 3B are incorrectly reversed. The authors have provided the correct [Fig 3](#pone.0162421.g001){ref-type="fig"} here.

![**3A: One-way sensitivity analysis, risk and HT based strategy. Fig 3B: One-way sensitivity analysis, risk based strategy.** Legend Fig 3A and 3B: Presents the change in ICER (incremental costs per DALY averted) compared to the baseline when parameter input is either varied in a high and low bound or when parameter input is varied to an alternative scenario (presented as lower bound). Darker and lighter bars represent the change in ICER when a parameter is varied to a respectively lower value (or alternative scenario) and higher value compared to the baseline estimate. \*effect of treatment on SBP: -14.6, coverage of 100% for eligible patients and no disability loss for hypertension treatment. \^based on observed costs in a scenario when limited diagnostic testing and task-shifting from doctors to nurses\[[24](http://journals.plos.org/plosone/article?id=10.1371%2Fjournal.pone.0157925#pone.0157925.ref024)\]. Abbreviations: SBP: systolic blood pressure; CHD: coronary heart disease; LVH: left ventricle hypertrophy. noHT: no hypertension; HT1: hypertension stage 1; HT2: hypertension stage 2. All values for the parameters tested as well as resulting ICERs are reported in Tables K and L ([S1 File](http://journals.plos.org/plosone/article?id=10.1371%2Fjournal.pone.0157925#pone.0157925.s001)).](pone.0162421.g001){#pone.0162421.g001}

There is an error in Table 1. The row "Relative risk reduction (RRR0 per 10 mmHg SBP decrease" was incorrectly omitted. The publisher apologizes for this error.
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###### Input parameters for cost-effectiveness analyses.
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  -------------------------------------------------------------------------------------------- ------------------------------------------------- ------------------ ------------------ ------------------------------------------------------------
  **Population and risk factor distributions**                                                                                                                                         
                                                                                               **Proportion (SE)**                               **Average (SE)**   **Distribution**   **Source \#**
  **Age categories**                                                                                                                                                                   
  30--44 years old                                                                             0.37 (0.01)                                       35.8 (0.15)        Beta               Kwara HH survey
  45--59 years old                                                                             0.34 (0.01)                                       50.1 (0.15)        Beta               Kwara HH survey
  60--69 years old                                                                             0.19 (0.01)                                       62.5 (0.14)        Beta               Kwara HH survey
  70--79 years old                                                                             0.11 (0.01)                                       71.8 (0.17)        Beta               Kwara HH survey
  **Gender, male**                                                                             0.45 (0.01)                                       \-                 Beta               Kwara HH survey
  **Hypertension severity\^**                                                                                                                                                          
  No hypertension                                                                              0.77 (0.01)                                       114.0 (0.30)       Beta               Kwara HH survey
  Hypertension, stage 1                                                                        0.13 (0.01)                                       142.66 (0.56)      Beta               Kwara HH survey
  Hypertension, stage 2                                                                        0.11 (0.01)                                       173.49 (1.36)      Beta               Kwara HH survey
  **Total Cholesterol**                                                                                                                                                                
  TC \> 5 mmol/L                                                                               0.08 (0.01)                                       5.49 (0.05)        Beta               Kwara HH survey
  TC \< = 5 mmol/L                                                                             0.92 (0.01)                                       3.66 (0.02)        Beta               Kwara HH survey
  **High Density Lipoprotein Cholesterol**                                                                                                                                             
  TC \> 5 mmol/L\*                                                                             0.08 (0.01)                                       1.36 (0.09)        Beta               Kwara HH survey
  TC \< = 5 mmol/L\*                                                                           0.92 (0.01)                                       1.08 (0.02)        Beta               Kwara HH survey
  **Current daily smoking**                                                                    0.12 (0.01)                                       N.A.               Beta               Kwara HH survey
  **Diabetes**                                                                                 0.04 (0.01)                                       N.A.               Beta               Kwara HH survey
  **Probabilities and outcomes in model**                                                                                                                                              
  **Stroke event**                                                                             **Base Case**                                     **Range**          **Distribution**   **Source \#**
  Probability of stroke event                                                                  Framingham risk score per risk profile per year   \[26\]                                
  Probability of stroke to be fatal within one year                                            0.53                                              0.50--0.57         Triangular         \[30--42\]
  Survival time if stroke fatal within one year                                                82.0 days                                         77.6--89.6 days    Triangular         \[30--42\]
  Survival time if stroke non-fatal within one year                                            Age- and gender-specific, adapted to Nigeria      \[43,44\]                             
  **CHD event**                                                                                **Base Case**                                     **Range**          **Distribution**   **Source \#**
  Probability of CHD event                                                                     Framingham risk score per risk profile per year   \[25\]                                
  Probability of CHD to be fatal within one year                                               0.30                                              0.26--0.33         Triangular         \[16,45,46\]
  Survival time if CHD fatal within one year                                                   49.3 days                                         44.3--61.3 days    Triangular         \[16,45,46\]
  Survival time if CHD non-fatal within one year                                               Age- and gender-specific, adapted to Nigeria      \[44,47\]                             
  **Other death**                                                                                                                                **Distribution**   **Source \#**      
  Probability of non-CVD mortality per year                                                    Age- and gender-specific table in supplement      \[44\]                                
  **Hypertension treatment**                                                                   **Base Case**                                     **Range**          **Distribution**   **Source \#**
  Coverage in KSHI program                                                                     29%                                               \-                 \-                 Kwara HH survey
  SBP decrease--individuals on antihypertensive treatment (mmHg)                               -20                                               (-31.6---8.4)      Triangular         Kwara HH survey
  SBP decrease--screened hypertensive individuals, not on antihypertensive treatment (mmHg)    -2.4                                              (-6.0--0)          Triangular         Kwara HH survey
  **Relative risk reduction (RRR) per 10 mmHg SBP decrease**                                   **Base Case**                                     **Range**          **Distribution**   **Source \#**
  RRR Stroke--based on Lawes 30--44 years old                                                  2.38                                              2.13--2.63         Triangular         \[7\]
  RRR Stroke--based on Lawes 45--59 years old                                                  2                                                 1.92--2.04         Triangular         \[7\]
  RRR Stroke--based on Lawes 60--69 years old                                                  1.56                                              1.52--1.61         Triangular         \[7\]
  RRR Stroke--based on Lawes 70--79 years old                                                  1.37                                              1.32--1.43         Triangular         \[7\]
  RRR CHD--based on Lawes 30--44 years old                                                     1.92                                              1.54--2.38         Triangular         \[7\]
  RRR CHD--based on Lawes 45--59 years old                                                     1.67                                              1.56--1.75         Triangular         \[7\]
  RRR CHD--based on Lawes 60--69 years old                                                     1.33                                              1.27--1.39         Triangular         \[7\]
  RRR CHD--based on Lawes 70--79 years old                                                     1.25                                              1.191.32           Triangular         \[7\]
  RRR Stroke--based on Rapsomaniki                                                             1.16                                              1.14--1.18         Triangular         Calculated from\[48\]
  RRR CHD--based on Rapsomaniki                                                                1.16                                              1.15--1.18         Triangular         Calculated from\[48\]
  **Cost parameters (2012 US\$)**                                                                                                                                                      
                                                                                               **Base Case**                                     **Range**          **Distribution**   **Source \#**
  Cost of hypertension care per patient per year                                               112                                               101--126           Triangular         Adapted from \[24\]
  Cost of screening per person screened                                                        5                                                 4--6               Triangular         \[49\]
  Above-service delivery costs of insurance program management per patient per year            24                                                \-                 Triangular         KSHI program management
  Cost of acute care after a stroke per patient                                                380                                               242--1,556         Triangular         Base Case: UITH data, \[24\] Range: \[16,17,19,35,50--57\]
  Cost of follow up care after a stroke per patient per year                                   240                                               206--275           Triangular         \[24\]
  Cost of acute care after CHD event per patient                                               181                                               115--1,180         Triangular         Base Case: UITH data, \[24\] Range: \[16,17,19\]
  Cost of follow up care after CHD event per patient per year                                  278                                               235--320           Triangular         \[24\]
  **DALY assumptions**                                                                                                                                                                 
                                                                                               **Base Case**                                     **Range**          **Distribution**   
  Disability weight during survival period after a fatal stroke (death during first year)      0.553                                             0.363--0.738       Triangular         Adapted from \[27\]
  Disability weight during survival after a non-fatal stroke                                   0.256                                             0.021--0.553       Triangular         Adapted from \[27\]
  Disability weight during survival period after a fatal CHD event (death during first year)   0.180                                             0.135--0.250       Triangular         Adapted from \[27\]
  Disability weight during survival after a non-fatal CHD event                                0.09                                              0.022--0.234       Triangular         Adapted from \[27\]
  Disability weight while on antihypertensive treatment                                        0.031                                             0.017--0.05        Triangular         \[27\]
  -------------------------------------------------------------------------------------------- ------------------------------------------------- ------------------ ------------------ ------------------------------------------------------------
